Sarepta Therapeutics has provided information on the Essence clinical trial currently recruiting in Canada for boys with deletions amenable to exon 45 and exon 53 skipping. The purpose of this Phase III research study is to evaluate the safety and effectiveness of SRP-4045 and SRP- 4053, Sarepta’s exon 45- and exon 53-skipping investigational drugs.

Please see the Essence brochures for further details and FAQs:

1. Essence brochure – English
2. Essence brochure – French

Trial Sites:

Alberta Children’s Hospital: Recruiting

Calgary, Alberta, Canada, T3B 6A8

Contact: Trevor Rutschmann 403-955-3192 or Trevor.Rutschmann@albertahealthservices.com

Principal Investigator: Jean Mah, MD

Children’s and Women’s Health Centre of British Columbia: Recruiting

Vancouver, British Columbia, Canada, V6H 3V4

Contact: Conrado De Guzman – (604) 875-2345 ext. 6834 or conrado.deguzman@cw.bc.ca

Principal Investigator: Kathryn Selby, MD

London Health Sciences Centre: Recruiting

London, Ontario, Canada, N6A 5W9

Contact: Gina Bhullar – (519) 685-8500 ext. 55058 or gina.bhullar@lhsc.on.ca

Principal Investigator: Craig Campbell, MD

Children’s Hospital of Eastern Ontario (CHEO): Recruiting

Ottawa, Ontario, Canada, K1H 8L1

Contact: Rosa Ramos – rramos@cheo.on.ca
Principal Investigator: Hugh McMillan, MD